Checkmate Pharmaceuticals, Inc. CMPI
Set alert
10.50 +10.50 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -4.61
- Beta
- 0.00
- Short ratio
- 0.15
- Inst. own
- 77.51%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 12, 2022
- 50-d avg
- 8.60
- 200-d avg
- 4.78
- 1y target
- 12.50
Analyst view
Consensus: buy
Buy
Price target (mean) 12.50 +19.0% upside
Now 10.50
- Target (low)
- 6.00
- Target (mean)
- 12.50
- Target (high)
- 19.00
Recommendation trend
- 1 month ago 3
- 2 months ago 3
- 3 months ago 4
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.75 | -0.75 – -0.75 | -0.88 | +14.8% | 0 | 0.0% | 2 |
| Next quarter | -0.74 | -0.77 – -0.72 | -0.69 | -7.2% | 0 | 0.0% | 2 |
| Current year | -3.02 | -3.05 – -3.00 | -2.84 | -6.3% | 0 | 0.0% | 2 |
| Next year | -2.28 | -3.01 – -1.55 | -3.02 | +24.5% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 20, 2022 | BTIG | Downgrade | Buy | Neutral |
| Mar 30, 2022 | BTIG | Maintained | — | Buy |
| Oct 6, 2021 | B of A Securities | Upgrade | Neutral | Buy |
| Sep 1, 2020 | Bank of America | Initiated | — | Neutral |
| Sep 1, 2020 | Jefferies | Initiated | — | Buy |
| Sep 1, 2020 | BTIG | Initiated | — | Buy |
| Sep 1, 2020 | BMO Capital | Initiated | — | Outperform |